The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis

被引:7
|
作者
Xu, Wenhua [1 ,2 ]
Cui, Jiajun [1 ,3 ]
Wu, Linqing [1 ,4 ]
He, Caigu [1 ,5 ]
Chen, Gang [1 ]
机构
[1] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, MN306,800 Rose St, Lexington, KY 40536 USA
[2] Univ Sci & Technol China, Dept Neurol, Affiliated Hosp 1, Hefei 230001, Anhui, Peoples R China
[3] Yichun Univ, Coll Med, Dept Biochem, Yichun 336000, Jiangxi, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou 350003, Fujian, Peoples R China
[5] Fujian Univ Tradit Chinese Med, Dept Histol & Embryol, Fuzhou 361000, Fujian, Peoples R China
关键词
Arsenic; Lung; Tumor; T cell; PD-1; PD-L1; REGULATORY T-CELLS; CANCER; CD8(+); EXHAUSTION; PROLIFERATION; IMMUNOTHERAPY; LYMPHOCYTES; EXPRESSION; MODELS; PD-L1;
D O I
10.1016/j.taap.2021.115633
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic exposure to environmental arsenic promotes lung cancer. Emerging evidence indicates that compromised host immunity, particularly T cell anti-tumor immunity, may play a critical role in cancer development. However, there is a knowledge gap in terms of the effects of arsenic exposure on T cell anti-tumor immunity and how that may contribute to arsenic lung carcinogenicity. Immunosuppression has been known as a risk factor for many types of cancer, including lung cancer. The development of cancer indicates the success of immunosuppression and escape of cancer cells from host anti-tumor immunity in which T cells are the major component. The anti-tumor immunity is mainly executed by CD8 cytotoxic T cells through their anti-tumor effector function, which can be regulated by immune checkpoint pathways. Some inhibitory receptors on the T cell membrane and their ligands form these pathways, among which programmed death-1 (PD-1), a T cell inhibitory receptor, and its ligand, programmed death-ligand 1 (PD-L1), are best characterized. A/J mice are naturally sensitive to pulmonary carcinogens, prone to develop spontaneous lung tumors later in life and have been frequently used as an animal model for lung tumorigenesis research. Chronic arsenic administration through drinking water has been shown to enhance tumor formation in the lungs of A/J mice. In the current study, using this mouse model we want to determine whether PD-1/PD-L1 plays a role in arsenic-enhanced lung tumorigenesis. The results showed that prolonged arsenic exposure up-regulated PD-1/PD-L1, increased regulatory T cells (Tregs), decreased CD8/ Treg ratio, inhibited T cell antitumor function in the lungs and enhanced lung tumor formation, while inhibition of PD-1/PD-L1 restored CD8/Treg ratio and T cell anti-tumor effector function, and mitigated arsenic-enhanced lung tumorigenesis. In addition, inhibition of PD-1/PD-L1 could be a potential preventive strategy to mitigate the tumorigenic action of chronic arsenic exposure.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] PD-1/PD-L1 inhibitors
    Sunshine, Joel
    Taube, Janis M.
    CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
  • [22] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [23] Soluble PD-L1 levels correlate with efficacy of PD-1/PD-L1 inhibitors in lung cancer
    Kang, Da Hyun
    Koh, Jeong Suk
    Chung, Chaeuk
    Park, Dongil
    Lee, Song-I
    Lee, Jeong Eun
    RESPIROLOGY, 2023, 28 : 99 - 99
  • [24] Role of regulation of PD-1 and PD-L1 expression in sepsis
    Teng, Zhang
    Li, Yu-Jing
    Tao, Ma
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] PD-1/PD-L1 Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Bagley, Stephen J.
    Bauml, Joshua M.
    Langer, Corey J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (10) : 676 - 683
  • [26] Role for the PD-1/PD-L1 axis in the development of COPD
    Ritzmann, F.
    Vella, G.
    Angenendt, A.
    Lis, A.
    Herr, C.
    Bals, R.
    Beisswenger, C.
    PNEUMOLOGIE, 2020, 74 : S73 - S73
  • [27] PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
    Dermani, Fatemeh K.
    Samadi, Pouria
    Rahmani, Golebagh
    Kohlan, Alisa K.
    Najafi, Rezvan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1313 - 1325
  • [28] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [29] Dendrobine Suppresses Tumor Growth by Regulating the PD-1/PD-L1 Checkpoint Pathway in Lung Cancer
    Li, Linmao
    Nong, Jiejin
    Li, Jingui
    Fang, Lini
    Pan, Meini
    Qiu, Haixian
    Huang, Shiqing
    Li, Yepeng
    Wei, Meijuan
    Yin, Haiying
    CURRENT CANCER DRUG TARGETS, 2024,
  • [30] The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
    Wang, Qingshui
    Lin, Wei
    Tang, Xiaoqiong
    Li, Suhuan
    Guo, Libin
    Lin, Yao
    Kwok, Hang Fai
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (12)